MoonLake Immunotherapeutics (MLTX) stock
MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$12.50−0.37 (-2.87%)
Close on Nov 13, 2026Market cap $1.06BP/E –Yield –
MoonLake Immunotherapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
MoonLake Immunotherapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$273.36M. For fiscal 2025 it was -$242.22M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$242.22M | – |
| FY2024 | Dec 31, 2024 | -$141.71M | – |
| FY2023 | Dec 31, 2023 | -$53.75M | – |
| FY2022 | Dec 31, 2022 | -$64.90M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$78.95M | – |
| Q2 FY2026 | Jun 30, 2026 | -$60.76M | – |
| Q1 FY2026 | Mar 31, 2026 | -$69.18M | – |
| Q4 FY2025 | Dec 31, 2025 | -$64.47M | – |
| Q3 FY2025 | Sep 30, 2025 | -$70.69M | – |
| Q2 FY2025 | Jun 30, 2025 | -$59.96M | – |
| Q1 FY2025 | Mar 31, 2025 | -$47.11M | – |
| Q4 FY2024 | Dec 31, 2024 | -$49.22M | – |
| Q3 FY2024 | Sep 30, 2024 | -$42.76M | – |
| Q2 FY2024 | Jun 30, 2024 | -$30.24M | – |
| Q1 FY2024 | Mar 31, 2024 | -$19.49M | – |
See a number that looks wrong?